Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/19/22 | $300,000,000 | Series C |
Abu Dhabi Investment Authority Alaska Permanent Fund Altitude Life Science Ventures Artis Ventures Cormorant Asset Management Flagship Pioneering Hanwha Impact Partners Longevity Vision Fund March Capital Partners SALT Fund SoftBank Vision Fund 2 T. Rowe Price Associates | undisclosed |
